Uncontrolled activation of tumor necrosis factor receptor-associated factor (TRAF) proteins may result in profound tissue injury by linking surface signals to cytokine release. Here we show that a ubiquitin E3 ligase component, Fbxo3, potently stimulates cytokine secretion from human inflammatory cells by destabilizing a sentinel TRAF inhibitor, Fbxl2. Fbxo3 and TRAF protein in circulation positively correlated with cytokine responses in subjects with sepsis, and we identified a polymorphism in human Fbxo3, with one variant being hypofunctional. A small-molecule inhibitor targeting Fbxo3 was sufficient to lessen severity of cytokine-driven inflammation in several mouse disease models. These studies identified a pathway of innate immunity that may be useful to detect subjects with altered immune responses during critical illness or provide a basis for therapeutic intervention targeting TRAF protein abundance. npg
A r t i c l e s TRAF proteins are critically involved in inflammation, innate and adaptive immune responses, and programmed cell death 1 . In addition to six well-characterized TRAF proteins (TRAF1-TRAF6), another homolog (TRAF7) has been identified 2 . All TRAF proteins have a common highly conserved C-terminal domain that mediates interactions with transmembrane TNF receptors (TNFR). TRAF proteins (with the exception of TRAF1) also contain an N-terminal RINGfinger domain. Identification of TRAF proteins has contributed substantially to the understanding of the molecular mechanisms of signal transduction emanating from the TNFR superfamily and the Toll-like receptor-interleukin-1 receptor (TLR-IL-1R) family 1 . TRAF family members also interact with CD40, RANK, I-TAC and p75 nerve growth factor receptors 1 . Specifically, TRAF2, TRAF5 and TRAF6 serve as adaptor proteins that link cell-surface receptors with downstream kinase cascades that, in turn, activate key transcription factors, including NF-κB, which via canonical signaling results in cytokine gene expression. The execution of this cascade in some cases involves TRAF-mediated polyubiquitination of adaptor protein RIP1, which recruits and stimulates IκB kinase leading to activation of NF-κB 3 . With an exaggerated immune response, TRAF-mediated cytokine release via this pathway leads to severe effects of edema, multiorgan failure and shock 4, 5 . Hence, TRAF proteins have a central role as they mediate signal transduction to elicit transactivation of genes linked to a multitude of downstream cytokines that profoundly regulate host responses [6] [7] [8] [9] [10] . These observations suggest that therapeutics designed to selectively downregulate the abundance of TRAF proteins in cells could govern proinflammatory responses.
Protein ubiquitination is a universal, inducible and reversible process in mammalian cells that regulates diverse processes by branding proteins for degradation, either by the 26S proteasome or the lysosome 11 . Ubiquitin conjugation to a target protein is a multistep process catalyzed by an E1 ubiquitin-activating enzyme, followed by ubiquitin transfer from an E1-activating enzyme to an E2-conjugating enzyme and last, generation of an isopeptide bond between the substrate's ε-amino lysine and the C terminus of ubiquitin catalyzed by an E3 ubiquitin ligase 12 . One of the emerging families of E3 ligases is the Skp-Cullin1-F box (SCF) superfamily that regulates cell-cycle progression, DNA repair and cell survival 13 . The SCF apparatus contains Rbx1 and Cullin1, which form a scaffold to link the E2 conjugating enzyme (Ubc) with a substrate-specificity module [14] [15] [16] . This substrate-specificity module contains Skp1 bound to an F box protein, the latter of which targets many substrates through phosphospecific domain interactions 17 . The F box proteins are subclassified as Fbxl or Fbxw proteins depending on the presence of a C-terminal leucine-rich repeat (LRR) motif or WD repeat motif, respectively, that are used for substrate recognition 16 . A third subclass of F box proteins contains other protein-interaction domains or no recognizable domains, termed F box only proteins (Fbxo) 16 . A recently identified member of the Fbxl subclass, Fbxl2, regulates lipogenesis and the mitotic program 18, 19 .
In the current study, we discovered a molecular interaction between two F box proteins that regulate cytokine secretion through TRAF protein stability. First, Fbxl2 acts as a crucial, panreactive inhibitor of TRAF function by mediating ubiquitination and degradation of A r t i c l e s TRAF proteins in epithelia and human monocytes. Second, Fbxl2 itself is targeted for disposal in cells by Fbxo3, thereby upregulating TRAF protein expression to trigger cytokine-mediated inflammation. Not only did we link Fbxo3 and TRAFs to elevated cytokine responses in the circulation of individuals with sepsis, but we also identified a subgroup of individuals with a hypomorphic Fbxo3 polymorphism with impaired cytokine production. These studies provide a new molecular model of regulating innate immunity, which for the first time to our knowledge, led to the development of a family of F box protein small-molecule antagonists that exert potent antiinflammatory activity.
RESULTS

Fbxl2 targets TRAFs for polyubiquitination
In the process of identifying substrates for Fbxl2, we observed that ectopic expression of this F box protein in a murine lung epithelial (MLE) cell line resulted in lower expression of TRAF1-TRAF6 and phospho-IκBα ( Fig. 1a) . Conditional expression of Fbxl2 in MLE cells using a doxycycline-inducible plasmid resulted in TRAF protein degradation in a time-dependent manner ( Fig. 1b) . In coimmunoprecipitation experiments where we subjected MLE cell lysates to Fbxl2 immunoprecipitation, all TRAF proteins were detected in Fbxl2 immunoprecipitates by immunoblotting ( Fig. 1c) . The results suggest that endogenous Fbxl2 interacts with TRAFs in epithelial cells. As a positive control, cyclin D3 precipitated with Fbxl2 (refs. 20, 21) . As Fbxl2 overexpression did not alter amounts of Bcl-2 and c-IAP1 proteins, they served as negative controls not binding to Fbxl2 (Fig. 1a,c) . Inclusion of purified Fbxl2 with the full complement of E1 and E2 enzymes plus ubiquitin (SCF-Fbxl2) was sufficient to generate polyubiquitinated TRAF species in vitro (Fig. 1d) . Similarly, we used cyclin D3 as a positive control and MAP2 (an Fbxl7 substrate; unpublished data) as a negative control in the in vitro SCF-Fbxl2 ubiquitination assay. Last, ectopic expression of Fbxl2 plasmid decreased TRAF protein half-life ( Fig. 1e) , but not amounts of mRNA encoding these proteins (data not shown).
To identify a common docking site in TRAF proteins that bind Fbxl2, we initially focused on molecular interaction between TRAF5 and Fbxl2. We cloned sequences encoding wild-type TRAF5 and several TRAF5 deletion mutants into a pcDNA3.1D/V5-his vector ( Supplementary Fig. 1a,b) . We immunoprecipitated Fbxl2 from MLE cell lysates using Fbxl2 antibody and coupled it to protein A/G beads. Then we incubated Fbxl2 beads with in vitro-synthesized His-V5-tagged TRAF5 variants (Supplementary Fig. 1b) . After washing the proteins, we eluted them and processed them for V5-TRAF5 immunoblotting (Supplementary Fig. 1b ). We determined that Fbxl2 bound within TRAF5 C-terminal residues 403-421, and sequence alignment of this region revealed conserved tryptophan and lysine residues in all TRAF proteins ( Supplementary Fig. 1b,c) . Next, we constructed C-terminal deletion mutants for other TRAF proteins. The TRAF C-terminal deletion mutants devoid of this conserved region lost the ability to bind Fbxl2 (Supplementary Fig. 1d-h) . Last, in mutagenesis studies when we substituted the conserved tryptophan in TRAF1-TRAF6 proteins with alanine, we observed substantially weaker interaction between Fbxl2 and TRAF1-TRAF6 mutants ( Supplementary Fig. 1i ). These binding studies ( Supplementary  Fig. 1j ) indicated that the tryptophan site in TRAF1-TRAF6 serves as a critical docking site for Fbxl2 interaction. Last, we identified putative ubiquitin acceptor sites in TRAF2-TRAF6 and observed that expression of TRAF protein variants containing mutations at various acceptor lysine residues confers greater protein stability in cycloheximide-based half-life studies (Supplementary Fig. 2) .
To assess the biological function of Fbxl2, we monitored U937 human macrophage cytokine release upon lipopolysaccharide (LPS) challenge. First we transfected cells with empty vector or FBXL2containing plasmid for 24 h before exposure to LPS (100 ng/ml) for an additional 24 h. Using a human cytokine array, we assayed 36 cytokines .   f   e   TRAF1 TRAF2 TRAF3 TRAF4 TRAF5 TRAF6   16   12   8   4 TRAF protein half-life (h) IL-2  IL-4  IL-5  IL-6  IL-8  IL-10  IL-12 p70  IL-13  IL-16  IL-17  IL-17E  IL-23  IL-27  IL-32a  IP-10  I-TAC  MCP-1  MIF  MIP-1a  MIP-1b  Serpin E1  RANTES  SDF-1  TNF-α  Sterm- 
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A r t i c l e s Fbxl2 expression in cells transfected with the plasmid, compared to cells with empty vector, downregulated the vast majority of cytokine proteins released after LPS challenge ( Fig. 1f) . We recapitulated these findings in primary human peripheral blood mononuclear cells (PBMCs) transfected with either empty vector or FBXL2-containing plasmid for 12 h before exposure to LPS (2 µg/ml) for an additional 18 h. LPS treatment substantially increased TRAF protein amounts, but FBXL2 plasmid overexpression resulted in variable suppression of TRAF protein under unstimulated conditions and robustly blocked LPS induction of TRAF1-TRAF6 proteins in PBMCs ( Supplementary  Fig. 3a) . In a complementary approach, when we transfected U937 cells with Fbxl2 short hairpin RNA (shRNA) before exposure to LPS, Fbxl2 knockdown increased several inflammatory cytokines including GM-CSF (3.2-fold), IL-6 (8.5-fold), IFN-γ (1.5-fold), IL-17 (3.5-fold), IL-23 (1.5-fold) and MIP-1β (8.7-fold) compared to LPS treatment alone (data not shown). Fbxl2 knockdown increased TRAF1-TRAF6 protein in resting cells and generally augmented LPS-mediated induction of TRAF proteins; these effects were associated with activation of key downstream signaling molecules including phospho-JNK and phospho-IKKα in both unstimulated and LPS-stimulated U937 cells ( Supplementary Fig. 3b ). Thus, Fbxl2 may act as an inhibitor of TRAF protein activation by mediating TRAF1-TRAF6 protein cellular disposal to modulate downstream kinase signaling. Because cytokine secretion from cells fluctuated with time, this raised the possibility that F box protein abundance also varied; we therefore investigated Fbxl2 proteolysis. Fbxl2 protein had a short lifespan (half-life of 2.5 h), was polyubiquitinated at Lys201 and degraded in the proteasome (Supplementary Fig. 4 ).
Fbxl2 is phosphorylated and targeted by Fbxo3 SCF-based E3 ligases target phosphoproteins. Database analysis indicated many potential phosphorylation sites in the primary sequence of Fbxl2 ( Fig. 2a ). To confirm that Fbxl2 is a phosphoprotein, we lysed MLE cells, subjected them to Fbxl2 immunoprecipitation and then using phosphothreonine antibodies detected a band that migrated at the predicted size of Fbxl2 ( Fig. 2b) . To identify the potential kinase that targets Fbxl2 for phosphorylation, we subjected MLE cell lysates to Fbxl2 immunoprecipitation followed by immunoblotting for kinases. Of the seven kinases tested, glycogen synthase kinase (GSK3β) was the only protein detected in the Fbxl2 immunoprecipitates ( Fig. 2c) . GSK3β phosphorylated Fbxl2 in vitro (Fig. 2d) .
Because SCF-based E3 ligases target phosphoproteins 17 , we embarked on an unbiased screen randomly testing F box proteins that might mediate Fbxl2 ubiquitination and degradation. Upon overexpression of these proteins, only Fbxo3 decreased immunoreactive levels of Fbxl2 (data not shown). To date, only one study has shown that Fbxo3 increases ubiquitination of a target protein (p300), and Fbxo3 authenticity as an SCF subunit and its substrates remain unknown 22 . To confirm the specificity of Fbxo3 targeting Fbxl2, we performed co-immunoprecipitation experiments where Fbxo3 was detected in the Fbxl2 immunoprecipitates from MLE cells ( Fig. 2e) . The SCF-Fbxo3 complex directly induced Fbxl2 polyubiquitination in vitro (Fig. 2f) . Fbxo3 depletion increased Fbxl2 half-life, whereas Fbxo3 plasmid overexpression destabilized Fbxl2 protein in MLE cells ( Fig. 2g) . Fbxo3 knockdown effectively Fbxo3   TRAF1   TRAF2   TRAF3   TRAF4   TRAF5   TRAF6 Actin Input Fbxl2 . After transfection, cells were exposed to cycloheximide (40 µg/ml) for up to 4.5 h before collecting and processing for immunoblotting. (h) Immunoblot analysis for Fbxo3, TRAF and actin in lysates of U937 cells transfected with either control shRNA or two different Fbxo3 shRNAs (1 and 2) for 48 h and then exposed 100 ng/ml LPS for an additional 18 h. Data are representative of two experiments (b,d-g), one experiment (c) and three experiments (h).
A r t i c l e s decreased TRAF1-TRAF6 protein in both unstimulated and LPSstimulated U937 cells ( Fig. 2h) . Fig. 5a ), we performed mapping studies by immunoprecipitating Fbxo3 from MLE cell lysates using Fbxo3 antibody and coupled it to protein A/G beads. Then we incubated Fbxo3 beads with in vitro-synthesized V5-tagged Fbxl2 mutants. After washing the proteins, we eluted them and processed them for V5 immunoblotting. Fbxo3 docked at the C terminus (residues 390-410) of Fbxl2 ( Supplementary  Fig. 5b-d) . To confirm that this region is important for Fbxl2 stability, we tested wild-type Fbxl2 and several Fbxl2 C-terminal deletion or point mutants for stability ( Supplementary Fig. 5e,f) . Notably, an Fbxl2(∆C390-423) deletion mutant exhibited a prolonged half-life compared to wild-type Fbxl2, suggesting that residues 390-423 are important for its stability. Consistent with the ability of SCF-based E3 ligase subunits to directly interact with phosphodegrons in their substrates, Thr404 in Fbxl2 served as a target site for the Fbxo3 interaction, as Fbxl2(T404A) lost the ability to bind Fbxo3 ( Supplementary  Fig. 5d ), exhibited a prolonged half-life ( Supplementary Fig. 5f ) and exhibited substantial resistance to SCF-Fbxo3 in vitro ubiquitinylating activity (Supplementary Fig. 5g ). To confirm that Thr404 is an authentic Fbxl2 phosphorylation site, we subjected lysates of cells transfected with plasmids encoding either wild-type Fbxl2 or Fbxl2(T404A) to V5-Fbxl2 immunoprecipitation and then immunoblotted using phospho-threonine antibodies; we detected a substantial decrease in Fbxl2(T404A) protein phosphorylation compared to wild-type Fbxl2 (Supplementary Fig. 5h ). In summary, we found that Fbxo3 uses Thr404 of Fbxl2 as a molecular signature to recruit the SCF complex to polyubiquitinate Fbxl2 at a Lys201 acceptor site (Supplementary Fig. 5i ).
Using various Fbxl2 deletion variants (Supplementary
Fbxo3 contains a naturally occurring polymorphism at Val221
An analysis of human SNP database revealed a naturally occurring nonsynonymous C/T polymorphism (rs1402954) in FBXO3 (V221I) in individuals of of European descent with an allele frequency of 6.2% ( Table 1) . To evaluate the biological relevance of a V221I polymorphism in Fbxo3 in human cells, we analyzed PBMCs from healthy Caucasian subjects. We extracted genomic DNA from PBMCs followed by genotyping using a specific primer and probe set. As expected, eight PBMCs were heterozygous for the gene encoding Fbxo3(V221I) among the sixty samples screened ( Fig. 3a) . Compared to results in wild-type PBMCs, the induction of IL-1β, tumor necrosis factor (TNF) and IL-6 were significantly lower in PBMCs with the Fbxo3(V221I) variant after LPS challenge (Fig. 3b) . These functional differences in Fbxo3(V221I) PBMCs correlated with significantly less TRAF1, TRAF2, TRAF3, TRAF4 and TRAF6 proteins and more Fbxl2 protein ( Fig. 3c) . Thus, a naturally occurring human Fbxo3(V221I) polymorphism might confer a lower proinflammatory phenotype.
Fbxo3(V221I): loss-of-function F box protein polymorphism
To assess the behavior of Fbxo3(V221I), we measured ubiquitinylating activity of the F box protein. Compared to wild-type SCF-Fbxo3, the SCF-Fbxo3(V221I) complex exhibited a markedly lower ability to polyubiquitinate Fbxl2 with most of the substrate intact ( Fig. 4a) . By using U937 cells, which adopt the morphology and many characteristics of mature macrophages, Fbxo3 plasmid overexpression resulted in less Fbxl2 protein yet more of all six TRAF proteins ( Fig. 4b) .
Fbxo3 plasmid overexpression did not affect steady-state amounts of mRNA encoding TRAF1-TRAF6 (data not shown). However, overexpression of plasmid encoding Fbxo3(V221I) in U937 cells resulted in no change or only modestly more TRAF proteins ( Fig. 4b) . As a control, we identified another Fbxo3 variant, Fbxo3(P109R), that when Noncoding strand is shown.
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A r t i c l e s overexpressed led to greater amounts of TRAF protein comparable to that with wild-type Fbxo3 plasmid expression (data not shown). Thus P109R is not a loss-of-function substitution in Fbxo3. We also monitored U937 cell cytokine release by array upon LPS challenge after transfecting cells with LacZ plasmid, or plasmids encoding Fbxo3 or Fbxo3(V221I) for 24 h before exposure to LPS. Fbxo3 plasmid transfection stimulated elevated secretion of the majority of cytokines tested after LPS challenge. In contrast, expression of Fbxo3(V221I) did not dramatically alter cytokine release from cells compared to that in cells with the LacZ control plasmid (Supplementary Fig. 6a ).
Hence, in vitro studies suggest that Fbxo3(V221I) is a loss-of-function polymorphism of Fbxo3. As an acute cytokine storm contributes to tissue injury, the results raise the possibility that in vivo this polymorphism might alter host inflammatory responses or vulnerability to inflammatory injury. To extend the above observations in vivo, we infected mice with an empty lentivirus or a lentivirus containing genes encoding either Fbxo3 or Fbxo3(V221I) for 120 h (10 7 plaque-forming units (PFU) per mouse, intratracheally) and challenged these mice with Pseudomonas aeruginosa (strain PA103, 10 4 colony-forming units (CFU) per mouse, intratracheally) for an additional 24 h. After killing the mice we analyzed parameters of inflammatory injury. Wild-type Fbxo3 lentiviral plasmid expression, but not Fbxo3(V221I) lentiviral plasmid, augmented PA103-induced lung injury. Specifically, Fbxo3 gene transfer significantly increased lavage protein concentration and cell counts (Fig. 4c,d) . In addition, Fbxo3 plasmid overexpression in vivo significantly increased lavage cytokine levels compared to mice that received an empty vector with PA103 infection (Fig. 4e) . Mice ectopically expressing Fbxo3 also had a significantly lower survival rate after PA103 infection compared to mice infected with PA103 alone (Fig. 4f) . Lastly, Fbxo3 plasmid overexpression resulted in significantly more lung cell infiltrates in mice (Fig. 4g) . These biological effects were less pronounced after gene transfer of the Fbxo3(V221I)-encoding plasmid, which supports the finding that Fbxo3(V221I) is a lossof-function polymorphism of an F box protein. Thus, Fbxo3 triggers proinflammatory effects in a model of Pseudomonas pneumonia.
Fbxo3 knockdown ameliorates Pseudomonas lung injury
To assess a requirement of Fbxo3 in pneumonia, we pursued in vivo knockdown studies of mice infected with lentivirus encoding a nontargeting shRNA or an shRNA targeted to Fbxo3 (here called Fbxo3 shRNA) for 120 h (10 7 PFU/mouse, intratracheally) and then challenged with PA103 for an additional 24 h. Fbxo3 knockdown significantly ameliorated adverse effects of PA103 on lung mechanics as depletion of Fbxo3 led to greater compliance and lower lung resistance with lower elastance (Fig. 5a-d) . Fbxo3 knockdown also decreased lavage protein concentration, lavage cell counts and cell infiltrates ( Fig. 5e-g) . Mice receiving Fbxo3 shRNA had lower lavage cytokine amounts after PA103 infection and had increased survival compared to mice receiving a nontargeting shRNA (Fig. 5h,i) . These in vivo studies suggest that endogenous Fbxo3 is essential in mediating cytokine-driven inflammation during microbial infection.
To assess specificity of our model, we stimulated Fbxo3-depleted U937 cells with the synthetic lipopeptide Pam 3 CSK 4 and with TNF. Briefly, we first transfected U937 cells with either control shRNA or Fbxo3 shRNA for 48 h, then exposed the cells to either Pam 3 CSK 4 (500 ng/ml) or TNF (20 ng/ml) for an additional 18 h ( Supplementary  Fig. 6b,c) . To assay mediator secretion, we collected and assayed (Supplementary Fig. 6b) . And of the proteins induced by TNF, CD40L, CCL1, IL-1α, IL1-β, IL-23 and serpin E1 were suppressed by Fbxo3 knockdown (Supplementary  Fig. 6c ). Thus, depletion of endogenous Fbxo3-TRAF pathway in subjects with sepsis We assayed proinflammatory cytokines in plasma from seven control subjects, including two control individuals mechanically ventilated without acute lung injury, and from 16 subjects with sepsis. All subjects with sepsis met the definition evidenced by the presence of a systemic inflammatory response associated with infection confirmed by culture (or strongly suspected) with or without signs of hypoperfusion or organ dysfunction 23 ( Supplementary Table 1 ). Four subjects with sepsis had positive blood cultures for pathogens, and the majority of the remaining subjects had evidence of localizing pulmonary, gastrointestinal or urinary sources of infection. Subjects with sepsis had significantly elevated plasma levels of TNF, IL-1β and IL-6 ( Fig. 6a) . We analyzed TRAF1-TRAF6, Fbxl2 and Fbxo3 protein content by immunoblotting in circulating white blood cells from six control subjects and ten subjects with sepsis with available leukocytes. Subjects with sepsis had significantly more TRAF2, TRAF4, TRAF5, TRAF6 and Fbxo3 proteins and less immunoreactive Fbxl2 protein in cells versus control subjects (Fig. 6b) . We also extracted genomic DNA from 16 subjects with sepsis for genotyping; in this group we identified two subjects harboring an Fbxo3(V221I) polymorphism (heterozygous). In accordance with its putative hypofunction, the Fbxo3(V221I) subjects expressed less plasma TNF, IL-1β and IL-6 protein than the subjects with wild-type Fbxo3 (Fig. 6a) . These results suggest that the Fbxo3-TRAF pathway is functional in individuals with systemic inflammation.
Small molecule-mediated inhibition of Fbxo3
Fbxo3 has a 125-amino-acid bacterial-like ApaG domain in its C terminus, the function of which is unknown. Structural analysis of different ApaG proteins revealed a fold of several beta-sheets. Deletion mapping indicated that the Fbxo3-ApaG signature was required for ubiquitination of Fbxl2 (data not shown). Based on molecular docking and best-fit analysis of suitable Fbxo3 ligands, we selected benzathine as a backbone to develop small-molecule inhibitors (Fig. 7a) . One such molecule, termed BC-1215, scored high in docking studies with Fbxo3-ApaG, and it exhibited a low half-maximal inhibitory concentration (IC 50 ; 0.9 µg/ml) with regard to IL-1β release and a high half-maximal lethal concentration (LC 50 ; 87 µg/ml) in vitro (Fig. 7b) . BC-1215 decreased Fbxo3-Fbxl2 interaction in a dose-dependent manner and prevented SCF-Fbxo3-catalyzed Fbxl2 ubiquitination (data not shown). BC-1215 effectively lowered amounts of TRAF1-TRAF6 protein (Supplementary Fig. 7a ) without altering mRNAs encoding TRAF1-TRAF6 (data not shown). BC-1215 not only decreased TRAF1-TRAF6 protein under resting conditions, but also blocked LPS-mediated induction of TRAF1-TRAF6 proteins in PBMCs (Supplementary Fig. 7b) . BC-1215 also blunted induction of TRAF1-TRAF6 proteins after ectopic expression of Fbxo3 plasmid in U937 cells (Supplementary Fig. 7c) . Thus, BC-1215 inhibited the Fbxo3-TRAF activation pathway by destabilizing TRAF1-TRAF6. (Supplementary Fig. 7d ).
Anti-inflammatory activity of a Fbxo3 inhibitor
To assess in vivo anti-inflammatory activity, we first tested the effects of administering BC-1215 in a model of a cecal ligation and puncture (CLP)-induced sepsis. Mice with CLP had significantly increased cytokine release compared to sham-treated mice. Treatment with BC-1215 significantly attenuated CLP-induced secretion of all three circulating proinflammatory cytokines in mice (Fig. 7c) . BC-1215 also decreased bacterial counts in the CLP model ( Fig. 7d) and modestly inhibited bacterial growth as determined using Kirby-Bauer testing (data not shown). Finally, we administered BC-1215 in a pneumonia model, where it substantially ameliorated adverse effects of PA103 on lung mechanics (data not shown). BC-1215 administration resulted in substantially lower lavage protein concentration, lower lavage cell counts and less cell infiltrates after PA103 infection ( Fig. 7e-g) . These beneficial effects of the agent were associated with significantly lower lavage proinflammatory cytokine levels in PA103-infected mice (Fig. 7h) . We observed similar effects of BC-1215 in an H1N1 pneumonia model (data not shown). Hence, small-molecule targeting of the Fbxo3-TRAF pathway lowered the severity of cytokine-driven inflammation in preclinical models (Fig. 8) .
DISCUSSION
Cytokine-driven inflammation is a hallmark of severe infectious and noninfectious disorders that can contribute substantially to tissue injury. Here we provided evidence for two indispensible molecular inputs, Fbxo3 and Fbxl2, into TRAF-mediated signaling for cytokine gene expression. The data authenticate Fbxo3 as an E3 ligase subunit that triggers ubiquitination and degradation of another E3 ligase subunit, Fbxl2, thereby increasing amounts of TRAF proteins. The SCF-Fbxl2 complex acts as a counter-regulatory repressor of inflammation by destabilizing TRAF proteins. Specifically, Fbxl2 targeted TRAF1-TRAF6 for ubiquitination and degradation using a conserved molecular signature, which led to less cytokine secretion in inflammatory cells. In turn, Fbxo3 opposed Fbxl2 activity by specifically targeting it for ubiquitination and degradation to stimulate cytokine release. Targeting was facilitated by GSK3β phosphorylation of Fbxl2, this provides a phosphodegron molecular signal for Fbxo3 recruitment to Fbxl2. In addition, our data revealed a naturally occurring hypofunctional Fbxo3(V221I) polymorphism. Human monocytes expressing this polymorphism exhibited lower sensitivity to endotoxin stimulation. These data may be clinically relevant because subjects with sepsis exhibited activation of the Fbxo3-TRAF pathway in circulating leukocytes that correlated with elevated proinflammatory cytokines in plasma. The discovery of Fbxo3 as a stimulator of TRAF signaling provided the mechanistic platform that led to the design, synthesis and biological evaluation of an F box small-molecule inhibitor that exerted robust anti-inflammatory activity by impairing cytokine release in vivo. The effectiveness of this inhibitor underscores the physiological importance of the Fbxo3-Fbxl2 pathway in regulating inflammation.
Individual TRAF proteins may exert very distinct functions, and F box protein regulation of this family might lead to divergent biological responses affecting long-term adaptive immunity or the innate immune system depending on the cell type, the surface receptor or the predominant TRAF protein that is modulated by any given stimulus 24 . For example, overexpression of TRAF2 and TRAF5 can activate NF-κB canonical signaling 25 . TRAF3 is highly conserved with TRAF2 and TRAF5, but TRAF3 overexpression does not activate the NF-κB pathway and it negatively regulates TLR-stimulated proinflammatory cytokine release [26] [27] [28] . Splice variants with altered Zn 2+ -finger domains of TRAF3 do activate the NF-κB pathway 29 . Thus, the ability of F box proteins to elicit specific innate or adaptive effector functions will depend on differences in the availability of these intermediary adaptors within any given cell population.
Aside from TRAF1, TRAF proteins function as ubiquitin E3 ligases through their RING dimerization interface that mediate Lys63 polyubiquitination of adaptor molecules; TRAFs are also prone to ubiquitination by a HECT-type E3 Smad ubiquitination regulation factor 1 and Triad3A 30, 31, 32 . An E3 ligase can target multiple proteins for ubiquitination, and different E3 ligases can target the same substrate 33 . Here one E3 ligase subunit (Fbxl2) in the SCF E3 ligase complex ubiquitinates several TRAF proteins. Thus, given the common Fbxl2 docking site identified in TRAF proteins, our data are not inconsistent with the promiscuity of some F box proteins and highlight a potentially fundamental role for this F box protein in regulating the innate immune response during agonist-induced inflammation.
The molecular behavior of Fbxo3 appears to be unique by virtue of its ability to target Fbxl2 for ubiquitination through its prokaryotic ApaG domain. Some components in the SCF machine are targeted by the ubiquitin ligase anaphase-promoting complex or by autoubiquitination within their own SCF complex 34, 35 . It is likely that Fbxo3 modulates the TRAF-cytokine axis through Fbxl2, but the results do not rule out other intermediary proteins that link Fbxo3 with TRAF proteins. Figure 8 Molecular regulation of proinflammatory cytokines mediated by F box proteins. Microbial infection or stimuli can robustly activate a variety of cell surface receptors linked to TRAF proteins that serve as critical intermediary signaling proteins to mediate cytokine synthesis and release. The F box protein Fbxl2 serves as a sentinel inhibitor of TRAFs by mediating their polyubiquitination (red circles) and proteasomal degradation in cells. Fbxl2 specifically targets at a conserved tryptophan domain within all TRAF1-TRAF6. During microbial infection Fbxo3 targets Fbxl2 for its ubiquitination and degradation at Lys201; this process is facilitated by glycogen synthase kinase (GSK3β) phosphorylation (green circle) of Fbxl2 at Thr404. Wild-type (WT) Fbxo3 in this pathway potently activates cytokine-driven inflammation, whereas we identified a naturally occurring variant of human Fbxo3 that is a polymorphism that is hypofunctional (Fbxo3(V221I)) with lower amounts of cytokine secretion. A small-molecule Fbxo3 inhibitor, BC-1215, lowered inflammation by antagonizing actions of Fbxo3 on TRAF-cytokine signaling.
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A r t i c l e s
The Fbxo3 ApaG domain served as the mechanistic centerpiece and structural basis for our drug design to test actions of F box inhibitors. This domain is present in various species of bacteria such as Xanthomonas, Vibrio and Salmonella, where it is postulated to interact with pyrophosphate, nucleotide phosphates or heavy metals 36 . The ApaG domain to date has been identified only within some F box proteins and PDIP38, a protein that interacts with proliferating cell nuclear antigen 37, 38 . By adding a pyridine group to the benzathine backbone we generated BC-1215, which optimally interacted with ApaG to profoundly inhibit secretion of a broad spectrum of T H 1 cytokines from human PBMCs. Indeed, structure-activity analysis led to synthesis of several modified Fbxo3 antagonists that exhibited potent anti-inflammatory activities (data not shown).
Our model of Pseudomonas induced pneumonia in mice was recapitulated, in part, with observations in humans with sepsis, underscoring the biologic relevance of the Fbxo3-TRAF pathway for cytokine secretion. Functional characterization of PBMCs from eight human individuals harboring Fbxo3(V221I) polymorphisms unexpectedly showed that these cells do not fully retain cytokine responses to LPS stimulation. Because valine and isoleucine are similar branched-chain hydrophobic residues, the prediction is that such naturally occurring polymorphisms would not result in profound functional consequences. Notably, similar polymorphisms in ubiquitin-specific protease 26 are linked to human phenotypes 39 . All subjects identified in our studies were heterozygotes who had less immunoreactive Fbxo3, less TRAF proteins and low cytokine responses coupled with high Fbxl2 protein amounts. However, in these heterozygous subjects, TRAF5 levels were not altered compared to wild-type subjects, which may be attributed to the experimental design and kinetics of TRAF5 expression or its unique molecular regulation. It is possible that heterozygotic Fbxo3(V221I) polymorphisms confer a selective biological advantage in silent carriers after microbial infection by limiting host inflammation that contributes to end-organ damage. This heterozygotic advantage with regard to cytokine secretion in cells expressing FBXO3(V221I) would mimic other genetic mutations such as sickle-cell anemia [40] [41] [42] . The inability to identify homozygous subjects expressing FBXO3(V221I) might be due to its genetic lethality with marked inability of subjects to recover from severe infection, as innate immunity might be considerably disarmed. Future studies will evaluate a larger cohort of subjects with sepsis and other immunological disorders and correlate expression of TRAF proteins, F box proteins and inflammatory responses to additional clinical endpoints. Ultimately the heterogeneity of cytokine responses across individuals that stem from Fbxo3-TRAF signaling might lend itself to personalized therapy using Fbxo3 inhibitors in subjects with inflammatory illness.
METHODS
Methods and any associated references are available in the online version of the paper.
